Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Concept

Follicular lymphoma

Related publications (30)

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

Elisa Oricchio

The HVEM (TNFRSF14) receptor gene is among the most frequently mutated genes in germinal center lymphomas. We report that loss of HVEM leads to cell-autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. HVEM-defi ...

Cell Press2016

Lymphotoxin-Dependent B Cell-FRC Crosstalk Promotes De Novo Follicle Formation and Antibody Production following Intestinal Helminth Infection

Nicola Harris, Lalit Kumar Dubey, Ilaria Mosconi, Luc Xavier Marie Lebon

Secondary lymphoid tissues provide specialized niches for the initiation of adaptive immune responses and undergo a remarkable expansion in response to inflammatory stimuli. Although the formation of B cell follicles was previously thought to be restricted ...

Elsevier2016

Notch Signaling Regulates the Homeostasis of Tissue-Restricted Innate-like T Cells

Freddy Radtke, Ute Koch

Although Notch signaling plays important roles in lineage commitment and differentiation of multiple cell types including conventional T cells, nothing is currently known concerning Notch function in innate-like T cells. We have found that the homeostasis ...

American Association of Immunologists ; Oxford University Press2016

The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody

Pierre Vogel, Somi Reddy Majjigapu

APO866 is an inhibitor of nicotinamide adenine dinucleotide (NAD) biosynthesis that exhibits potent anti-lymphoma activity. Rituximab (RTX), an anti-CD20 antibody, kills lymphoma cells by direct apoptosis and antibody- and complement-dependent cell-mediate ...

Informa Healthcare2014

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

Elisa Oricchio

Loss of cell cycle controls is a hallmark of cancer and has a well-established role in aggressive B cell malignancies. However, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individual lesions have been observed with low freq ...

2014

A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis

Pierre Vogel, Somi Reddy Majjigapu

APO866, an inhibitor of NAD biosynthesis, exhibits potent antitumor properties in various malignancies. Recently, it has been shown that APO866 induces apoptosis and autophagy in human hematological cancer cells, but the role of autophagy in APO866-induced ...

Landes Bioscience2014

Functional genomics lead to new therapies in follicular lymphoma

Elisa Oricchio

Recent technological advances allow analysis of genomic changes in cancer in unprecedented detail. The next challenge is to prioritize the multitude of genetic aberrations found and identify therapeutic opportunities. We recently completed a study that ill ...

2013

Progress against follicular lymphoma

Elisa Oricchio

To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma. ...

Lippincott, Williams & Wilkins2013

Notch Signaling Regulates Follicular Helper T Cell Differentiation

Freddy Radtke, Ute Koch, Nicolas Fasnacht

Follicular helper T (TFH) cells are specialized in providing help for B cell differentiation and Ab secretion. Several positive and negative regulators of TFH cell differentiation have been described but their control is not fully understood. In this study ...

American Association of Immunologists ; Oxford University Press2013

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

Oliver Hantschel

Constitutive activation of STAT5 is critical for the maintenance of chronic myeloid leukemia (CML) characterized by the BCR-ABL oncoprotein. Tyrosine kinase inhibitors (TKIs) for the STAT5-activating kinase JAK2 have been discussed as a treatment option fo ...

Nature Publishing Group2012